Matches in UGent Biblio for { <https://biblio.ugent.be/publication/5741770#aggregation> ?p ?o. }
Showing items 1 to 42 of
42
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B990734.
- aggregation creator B990735.
- aggregation creator B990736.
- aggregation creator B990737.
- aggregation creator B990738.
- aggregation creator B990739.
- aggregation creator B990740.
- aggregation creator B990741.
- aggregation creator B990742.
- aggregation creator B990743.
- aggregation creator B990744.
- aggregation creator B990745.
- aggregation creator B990746.
- aggregation creator B990747.
- aggregation creator person.
- aggregation date "2008".
- aggregation hasFormat 5741770.bibtex.
- aggregation hasFormat 5741770.csv.
- aggregation hasFormat 5741770.dc.
- aggregation hasFormat 5741770.didl.
- aggregation hasFormat 5741770.doc.
- aggregation hasFormat 5741770.json.
- aggregation hasFormat 5741770.mets.
- aggregation hasFormat 5741770.mods.
- aggregation hasFormat 5741770.rdf.
- aggregation hasFormat 5741770.ris.
- aggregation hasFormat 5741770.txt.
- aggregation hasFormat 5741770.xls.
- aggregation hasFormat 5741770.yaml.
- aggregation isPartOf urn:issn:0250-7005.
- aggregation language "eng".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases".
- aggregation abstract "Background: Both hepatic arterial infusion (HAI) of chemotherapy and cetuximab (CET) have interesting activity for the treatment of colorectal cancer liver metastases (CRC-LM). Patients and Methods: Intravenous CET with HAI oxaliplatin (OXA) or i.v. Irinotecan (IRI) followed by HAI of infusion of folic acid modulated 5 fluorouracil 5-FU/l-FA was administered to patients (pts) with CRC-LM who had failed at least one line of prior chemotherapy. Results: Eight pts received i.v. CET with HAI-OXA (5 pts) and i.v.-IRI (3 pts) and HAI-5-FU/l-FA. Adverse events: repeated grade 3 skin toxicity (1 pt), abdominal pain with elevated liver enzymes and asthenia (2 pts), duodenal ulcer (2 pts) with catheter migration and intestinal bleeding (1 pt), reversible interstitial pneumonitis (1 pt), and cystic bile duct dilatation (2 pts) with arteriobiliary fistulisation (1 pt). A partial response was documented in 5 pts (62%). The median time to progression was 8.7 months (95% confidence interval 8-14 months). Conclusion: Intravenous administration of CET with HAI of chemotherapy is feasible and has promising activity but is associated with specific toxicity.".
- aggregation authorList BK1391919.
- aggregation endPage "2467".
- aggregation issue "4C".
- aggregation startPage "2459".
- aggregation volume "28".
- aggregation isDescribedBy 5741770.
- aggregation similarTo LU-5741770.